Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

Y0000855

Citalopram for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Citalopram hydrobromide, 1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile hydrobromide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C20H21FN2O · HBr
Numéro CAS:
59729-32-7
Poids moléculaire :
405.30
Numéro MDL:
MFCD02101306
Code UNSPSC :
41116107
ID de substance PubChem :
329831193
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

citalopram

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

Br[H].CN(C)CCCC1(OCc2cc(ccc12)C#N)c3ccc(F)cc3

InChI

1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H

Clé InChI

WIHMBLDNRMIGDW-UHFFFAOYSA-N

Informations sur le gène

human ... SLC6A4(6532)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Citalopram for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Potent and selective serotonin uptake inhibitor (Ki = 5.4 nM); antidepressant

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1134233

Citalopram hydrobromide, United States Pharmacopeia (USP) Reference Standard

1134244

Citalopram Related Compound A, United States Pharmacopeia (USP) Reference Standard

1134222

Citalopram Related Compound H, United States Pharmacopeia (USP) Reference Standard

1134197

Citalopram Related Compound G, United States Pharmacopeia (USP) Reference Standard

1134288

Citalopram Related Compound E, United States Pharmacopeia (USP) Reference Standard

1134266

Citalopram Related Compound C, United States Pharmacopeia (USP) Reference Standard

1134255

Citalopram Related Compound B, United States Pharmacopeia (USP) Reference Standard

1134277

Citalopram Related Compound D, United States Pharmacopeia (USP) Reference Standard

1134299

Citalopram Related Compound F, United States Pharmacopeia (USP) Reference Standard

Y0001008

Citalopram hydrobromide, European Pharmacopoeia (EP) Reference Standard

Y0001007

Citalopram hydrochloride, European Pharmacopoeia (EP) Reference Standard

PHR1640

Citalopram Hydrobromide, Pharmaceutical Secondary Standard; Certified Reference Material

1134142

R-Citalopram oxalate, United States Pharmacopeia (USP) Reference Standard

PHR1906

Citalopram Related Compound H, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1863

Citalopram Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1902

Citalopram Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1904

Citalopram Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1903

Citalopram Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

BP1153

Citalopram hydrobromide, British Pharmacopoeia (BP) Reference Standard

PHR1905

Citalopram Related Compound G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1901

Citalopram Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1154

Citalopram impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H336,H361d,H412

Classification des risques

Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - STOT SE 3

Organes cibles

Central nervous system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Yevheniia Mikheenko et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(6), 1395-1404 (2015-01-15)
Trait anxiety is a risk factor for the development and maintenance of affective disorders, and insights into the underlying brain mechanisms are vital for improving treatment and prevention strategies. Translational studies in non-human primates, where targeted neurochemical and genetic manipulations
Gordon F Buchanan et al.
The Journal of physiology, 592(19), 4395-4410 (2014-08-12)
Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in patients with refractory epilepsy. Defects in central control of breathing are important contributors to the pathophysiology of SUDEP, and serotonin (5-HT) system dysfunction may be involved. Here
M D Opal et al.
Molecular psychiatry, 19(10), 1106-1114 (2013-10-30)
Current antidepressants must be administered for several weeks to produce therapeutic effects. We show that selective serotonin 2C (5-HT2C) antagonists exert antidepressant actions with a faster-onset (5 days) than that of current antidepressants (14 days) in mice. Subchronic (5 days)
Laura Jiménez-Sánchez et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(11), 2673-2680 (2014-05-30)
Paradoxically, N-methyl-D-aspartate (NMDA) receptor antagonists are used to model certain aspects of schizophrenia as well as to treat refractory depression. However, the role of different subunits of the NMDA receptor in both conditions is poorly understood. Here we used biochemical
D Lindenbach et al.
British journal of pharmacology, 172(1), 119-130 (2014-09-02)
Treatment of Parkinson's disease (PD) with L-DOPA eventually causes abnormal involuntary movements known as dyskinesias in most patients. Dyskinesia can be reduced using compounds that act as direct or indirect agonists of the 5-HT1 A receptor, but these drugs have
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique